78results about "Vaccines" patented technology

Provided herein are novel Glypican 3 (GPC3) antibodies or antigen binding fragments and GPC3 / CD3 bispecific antibodies. The present application also provides chimeric antigen receptors comprising the antibodies or antigen-binding fragments, related CAR-T cells, and preparation methods and uses of the same. The present application further provides pharmaceutical compositions comprising GPC3 antibodies or antigen binding fragments, related GPC3 / CD3 bispecific antibodies, related GPC3 CAR or CAR-T cells, and methods of treating cancer in a subject in need thereof by administering the Glypican 3 (GPC3) antibodies or antigen binding fragments, the bispecific antibodies, the chimeric antigen receptors, the CAR-T cells, or the pharmaceutical compositions. The cancers treated in accordance with the application include Glypican-3-positive cancers.

Provided herein are cell surface receptors that include an extracellular binding domain, a transmembrane domain, an intracellular signaling domain, and a protease cleavage site disposed between the extracellular binding domain and the intracellular signaling domain. In certain aspects, the cell surface receptors are engineered cell surface receptors, such as chimeric antigen receptors (CARs). Also provided are cells that include such receptors (e.g., where the cells express the receptors on their surface) and pharmaceutical compositions including such cells. Nucleic acids that encode the cell surface receptors, cells including such nucleic acids, and pharmaceutical compositions including such cells, are also provided. Also provided are methods for regulating signaling of a cell surface receptor, and methods of using the cells of the present disclosure, including methods of using such cells to administer a regulatable cell-based therapy to an individual.

Treatment of Cancer Methods for treatment of cancer, in particular soft tissue sarcomas (STS), are described, as well as compounds, compositions, and combined preparations for use in such methods. An effective amount of: a LAG-3 protein, or a derivative thereof that is able to bind to MHC class II molecules; a programmed cell death protein-1 (PD-1) pathway inhibitor; and radiotherapy, is administered to a subject. Optionally the subject has undergone, is undergoing, or is to undergo, surgery for treatment of the cancer. A clinical trial study is described in which a triple combination of LAG-3 derivative eftilagimod alpha, a PD-1 pathway inhibitor, and radiotherapy was administered. The combination was surprisingly effective in the treatment of STS in patients who have completed 10 weeks of treatment, followed by surgery 2-3 weeks later. A substantial number of near complete pathological responses were observed, which are rarely seen in STS patients with standard therapeutic approaches including radiotherapy.

The present invention relates to methods for predicting T cell epitopes. In particular, the present invention relates to methods for predicting whether a modification in a peptide or polypeptide, such as a tumor-associated neoantigen, is immunogenic. The methods of the present invention are particularly suitable for providing a vaccine specific to a patient's tumor and, therefore, are suitable for use in the context of personalized cancer vaccines.

The present invention is directed to a humanized BCMA single-chain variable fragment (scFv), comprising VH having the amino acid sequence of SEQ ID NO: 4 and VL having the amino acid sequence of SEQ ID NO: 5. The present invention is also directed to a BCMA chimeric antigen receptor fusion protein comprising from N-terminus to C-terminus: (i) a single-chain variable fragment (scFv) of the present invention, (ii) a transmembrane domain, (iii) at least one co-stimulatory domains, and (iv) an activating domain. This humanized BCMA-CAR-T cells have specific killing activity with secretion of cytokine IFN-gamma in CAR-T cells in vitro and in vivo.

The present invention relates to the fields of molecular biology, virology, immunology and medicine, and in particular to a preparation method for a castrating AP205 virus-like particle subunit vaccine.

The present invention relates to the definition of a pool of antigenic sperm peptides of high species specificity for the regulation of water vole (Arvicola terrestris scherman) populations by a vaccine approach. Figure 1

The invention provides anti-Ara h 2 antibodies (e.g., an anti-Ara h 2 neutralizing antibody) and methods of using the same, e.g., for treating and / or preventing peanut allergy or sensitivity. Also provided herein are anti-Ara h 2 antibodies and methods of using the same, e.g., for diagnostics and methods of monitoring peanut oral immunotherapy.

The invention discloses a novel coronavirus variant RBD protein gene and application thereof. The method comprises the following steps: firstly, respectively constructing recombinant plant expression vectors pGt1-RBD and pGt1-RBDopt containing RBD and RBDopt genes, carrying out agrobacterium-mediated transformation to obtain a T0-generation transgenic rice plant, and carrying out T0-T3-generation screening and identification to obtain a transgenic rice plant capable of stably expressing RBD protein. The RBD protein is successfully expressed in rice endosperm and is subjected to N-glycosylation modification, and the content of the RBD protein in pGt1: RBDopt is obviously higher than that of pGt1: RBD. The pGt1:: RBDopt transgenic rice flour suspension is orally taken into an intragastric mouse, and experimental results show that the transgenic rice pGt1:: RBDopt can be used for developing oral vaccines of new crown vaccines and has a good application prospect.

This new chimeric antigen receptor (CAR) T-cell therapy effectively treats cancer while minimizing the risk of dangerous inflammatory responses such as cytokine release syndrome. [Solution] An isolated nucleic acid sequence encoding a CAR, wherein the CAR includes an antigen-binding domain specific to glypican 3 (GPC3), the antigen-binding domain has an equilibrium dissociation constant (KD) of approximately 100 nanomoles (nM) or less, and the CAR construct provides an isolated nucleic acid sequence that does not induce cytokine production in GPC3-expressing cells.

The invention belongs to the technical field of biological genetic transformation, and relates to a method for preparing recombinant foreign protein based on transient expression of fruits of cucurbitaceae crops. The efficient expression of the foreign protein is realized through the processes of constructing an instantaneous transformation vector, infecting fruits with agrobacterium and purifying the protein. The method overcomes the defects of high cost and low purity of a traditional tobacco transient expression system, has the advantages of easily available raw materials, large biomass, edibility, high safety and the like, and provides a new way for low-cost large-scale production of recombinant proteins.

The present invention relates to antigen-based immunotherapy targeting interleukin 13 receptor alpha 2 (IL13RA2), BIRC5 and / or FOXM1 for treatment of adrenal cancers. In particular, the present invention provides the use of a (poly)peptide comprising an epitope of IL13RA2, BIRC5 and / or FOXM1 or a sequence variant thereof for treatment of an adrenal cancer. Moreover, the present invention also provides combinations of the (poly)peptide comprising an epitope of IL13RA2, BIRC5 and / or FOXM1 or a sequence variant thereof with (poly)peptides comprising other epitopes or sequence variants thereof for treatment of adrenal cancers.

The present invention relates to the production of modified influenza vial proteins in plants. More specifically, the present invention relates to producing and increasing influenza virus-like particle (VLP) production in plants, wherein the VLPs comprise the modified influenza viral proteins, such as modified influenza hemagglutinin (HA). The HA protein may comprising an amino acid sequence comprising at least one substitution when compared to a corresponding wildtype amino acid sequence. Further provided are nucleic acid encoding the modified HA protein. Furthermore methods of producing an influenza virus like particle (VLP) and methods of increasing yield of production of an influenza virus like particle (VLP) in a plant, portion of a plant, or a plant cell, are also provided.

The present invention provides phagocytic particles for treating or preventing cancer in a subject, wherein the phagocytic particle comprises a core and a neoantigen construct tightly associated with the core, and wherein the neoantigen construct comprises a neoepitope peptide having an amino acid sequence corresponding to the amino acid sequence of a portion of a protein or peptide known or suspected to be expressed by a cancer cell in the subject, wherein the portion of the protein or peptide has at least one somatically mutated amino acid. The present invention also relates to an injectable pharmaceutical composition for treating or preventing cancer.

The present invention relates to a method of producing a binder-toxin fusion protein comprising at least, one protein binder selected from the group consisting of an antibody, an antibody fragment or derivative retaining target binding capacity, or an antibody mimetic, optionally, a peptide linker, and at least one protein toxin or protein protoxin. The method comprises the steps of: contacting a plant cell or a whole plant with a nucleic acid construct comprising in operational linkage at least the following (A) at least one polynucleotide encoding for the protein binder, or a target binding chain or domain thereof, and either B1) a polynucleotide encoding for a cleavable peptide linker and a polynucleotide encoding for a protein toxin, or B2) a polynucleotide encoding for a protein protoxin, which protoxin comprises a cleavable domain for activation thereof, allowing the construct to integrate into the nucleus of the plant cell, or of one or more cells of the whole plant, and expressing the fusion protein encoded by the nucleic acid construct (Fig. 7).

To provide methods and compositions for genetically modifying lymphocytes, for example, T cells and / or NK cells in a shorter time than before and / or in whole blood or a blood component.SOLUTION: The disclosure provides methods and compositions for genetically modifying lymphocytes, for example, T cells and / or NK cells in a shorter time than before, and / or in whole blood or in a blood component. In some embodiments, a lymphodepletion filter assembly is used before or after a reaction mixture is formed, and the lymphocytes are brought into contact with recombinant retrovirus particles in a closed system to genetically modify the lymphocytes.SELECTED DRAWING: None

The present invention relates to a method for producing a genetically modified plant, plant cell, protoplast, or plant tissue expressing a recombinant protein of interest, comprising at least the step of introducing into the plant, plant cell, protoplast, or plant tissue a plant nucleic acid construct that provides stable expression of the protein of interest, wherein the plant is selected from the genera Spinacia, Lactuca, and Brassica, preferably the plant is an edible plant from the genus Brassica, and the nucleic acid construct is a single synthetic construct that includes an operably linked DNA, an operably linked protein-encoding DNA molecule, and a regulatory sequence active in the plant for expression of the 3' untranslated region. The present invention also encompasses the nucleic acids, bacterial strains, and plants obtained according to the above method, as well as the plant-produced proteins obtained from the genetically modified plants of the present invention.

To provide an agent for the treatment for a metastatic brain tumor.SOLUTION: The present invention provides a therapeutic agent for a metastatic brain tumor comprising, as an active component, an antibody-drug conjugate in which a drug-linker represented by the following formula (where A represents a connecting position to an antibody) is conjugated to the antibody via a thioether bond, and / or a method for treatment for a metastatic brain tumor, comprising administering the antibody-drug conjugate to an individual in need of the treatment for the metastatic brain tumor.SELECTED DRAWING: Figure 9

The present invention relates to the definition of a pool of antigenic sperm peptides with high species specificity for regulating populations of water vole (Arvicola terrestris scherman) using a vaccine approach.

Provided herein are cell surface receptors that include an extracellular binding domain, a transmembrane domain, an intracellular signaling domain, and a protease cleavage site disposed between the extracellular binding domain and the intracellular signaling domain. In certain aspects, the cell surface receptors are engineered cell surface receptors, such as chimeric antigen receptors (CARs). Also provided are cells that include such receptors (e.g., where the cells express the receptors on their surface) and pharmaceutical compositions including such cells. Nucleic acids that encode the cell surface receptors, cells including such nucleic acids, and pharmaceutical compositions including such cells, are also provided. Also provided are methods for regulating signaling of a cell surface receptor, and methods of using the cells of the present disclosure, including methods of using such cells to administer a regulatable cell-based therapy to an individual.

The present disclosure provides compositions and methods of treating bone cancers, e.g., osteosarcoma in a patient whose age is, for example, at least 2 years old, or at least 12 years old. The method comprises promoting the opening of Cx43 hemichannel in osteocytes by, e.g., using a composition comprising an anti-connexin 43 antibody.

In some aspects there is described formulations for the treatment of fusion-positive alveolar rhabdomyosarcoma, methods of preparing thereof, and validating their immunogenic activity.

The present invention relates to a genetically modified plant or plant cell derived from a wild-type plant or plant cell, said wild-type plant or plant cell producing at least one serine protease comprising the motif SSRGPX1LKPDX2X3APGX4SGTSMSCPHX5PX6WSPX7AX8X9SAX10MTT (SEQ ID No. 1), whereinX1 is a peptide consisting of 7 amino acid residues, X2 is I or L, X3 is T or M, X4 is a peptide consisting of 27 or 28 amino acid residues, X5 is a peptide consisting of 12 amino acid residues, X6 is T or E, X7 is S or A, X8 is V or I, X9 is K or R and X10 is I or M, wherein the proteolytic activity of the at least one serine protease in the genetically modified plant or plant cell is reduced compared to its activity in the wild-type plant or plant cell, wherein the genetically modified plant or plant cell comprises at least one exogenous nucleic acid molecule encoding for at least one protein or polypeptide of interest.

Provided herein are cancer stem cell targeted cancer vaccines and methods for treating and vaccinating against cancer. Also contained herein are regimens by which cancer stem cell targeted cancer vaccines are administered, such regimens comprising peptides, compositions, immunomodulatory agents, and emulsifiers. Also provided are the patient populations to which the regimens are to administered, and the dosages, schedules, route of administration for the regimens.

The present invention provides a cell that co-expresses a first chimeric antigen receptor (CAR) and a second CAR on the cell surface, each CAR comprising an antigen binding domain, wherein the antigen binding domain of the first CAR binds CD19 and the antigen binding domain of the second CAR binds CD22.

The present invention provides a peptide vaccine pharmaceutical composition and method of use for stimulating an immune response against glioma H3K27M mutation. The peptide vaccine has a length of at least 12 amino acid residues, is capable of stimulating a CD4T cell response upon administration, optionally also capable of stimulating a CD8T cell response.

The present invention relates to a nucleic acid sequence with an elevated expression rate having at least one expression cassette for expression of a protein, wherein the expression cassette has at least one promoter element, and at least one first transcription unit that encodes at least one peptide, wherein the promoter element consists of nucleic acid sequence SEQ ID NO: 1 or of a nucleic acid sequence having at least 70% homology with SEQ ID NO: 1. The invention further relates to a vector or an isolated nucleic acid comprising at least one nucleic acid sequence of the invention in simple or repetitive form. The present invention additionally relates to an amino acid sequence comprising SEQ ID NO: 2 or an amino acid sequence having at least 70% homology with SEQ ID NO: 2, and to a cell comprising a vector of the invention or an isolated nucleic acid of the invention, or a nucleic acid sequence of the invention, or an amino acid sequence of the invention, wherein the cell is a photosynthetically active cell, especially a unicellular plant or Viridiplantae, preferably a diatom. The invention also relates to a screening method for selection of cells having an elevated expression rate of a nucleic acid sequence of the invention, and to a method of producing recombinant antibodies using a vector of the invention or an isolated nucleic acid of the invention and / or a nucleic acid sequence of the invention.

The present disclosure provides engineered immune cells or their precursors (e.g., T cells) comprising a chimeric antigen receptor (CAR) capable of binding to human IL13Rα2. Bispecific CARs, parallel CARs, tandem CARs, BiTEs, BiTE / CARs, and BiTE / BiTEs are also provided. Compositions and methods of treatment are also provided.

Provided is a diester lipid compound of Formula (I) or a pharmaceutically acceptable salt thereof The compound can be used to obtain lipid nanoparticles. In some embodiments, the lipid nanoparticle can comprise (a) from about 40 to about 100 mol % of the compound of Formula (I); (b) from 0 to about 10 mol % of a neutral lipid; (c) from 0 to about 50 mol % of a helper lipid; (d) from 0 to about 5 mol % of a polymer-conjugated lipid; and (e) from 0 to about 5 mol % of a hydrophobic component; wherein the mol % are based on the total lipids present in the nanoparticle. (I)

Disclosed herein are compositions including oncolytic bacterial rBMCs, and the use of the composition as in situ immunization agents against cancer. In some embodiments, the rBMCs are endowed with the ability to simultaneously stimulate upstream intracellular mediators of a cytokine response.